Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: a Multicenter Prospective Clinical Study

NCT06590740 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06590740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: a Multicenter Prospective Clinical Study
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 18, 2024
Completion date
September 3, 2025
Enrollment
1,000 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cough-variant asthma